DocGo Inc. (DCGO) delivers medical care and transportation straight to patients instead of requiring visits to clinics or hospitals. The company pairs clinicians with a proprietary dispatch and care platform to offer in-home urgent care, preventive services, chronic disease management, and non-emergency medical transport. I follow names like this because they sit at the crossroads of healthcare delivery, technology adoption, and the ongoing move toward care outside traditional hospital settings.
DocGo started in 2015 as Ambulnz with a focus on non-emergency medical transportation. It rebranded to DocGo in 2021 while expanding into broader mobile health services and became publicly traded on November 8, 2021, through a business combination with Motion Acquisition Corp. on the Nasdaq Global Market under the ticker DCGO. The headquarters remain in New York, New York.
The business runs through two reportable segments. The Mobile Health Services segment delivers care in homes, offices, and other non-traditional locations, covering mobile urgent care, vaccinations, screenings, remote patient monitoring, chronic disease management, and on-site event support. The Transportation Services segment handles emergency response along with non-emergency options such as ambulance and wheelchair transport, partly under the Ambulnz brand. When screening comparable names in the space, I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Revenue comes mainly from contracts with hospitals, health systems, insurers, municipalities, physician practices, and employers. Much of it flows through fee-for-service and contractual arrangements rather than direct patient billing. The technology platform coordinates clinicians and field staff, including EMTs, paramedics, and nurses, positioning the company as a last-mile provider. Primary operations are in the United States, with additional non-emergency ambulance work in the United Kingdom under National Health Service contracts.
DocGo stands out amid the broader shift toward decentralized, home-based, and value-based care. Health systems and payers continue seeking ways to lower readmissions and manage chronic conditions without relying on high-cost acute settings. The combination of its dispatch technology and extensive clinician network supports that positioning. Another factor is the mix of commercial and government clients plus movement into recurring models tied to health plans. From what I see, the mobile health side has grown to represent the larger share of revenue while the transportation segment provides a more established base.
The competitive landscape includes larger players in telehealth and in-home care such as Teladoc, DispatchHealth, ModivCare, and Option Care Health. Differentiation rests on scale, clinical quality, cost, and convenience. Government and municipal contracts have historically contributed a meaningful portion of revenue, and those arrangements can carry volatility or face regulatory shifts. Reimbursement changes, labor cost pressures, and broader macroeconomic influences on payer behavior all represent ongoing considerations. I’m watching this closely because workforce availability remains a notable variable in service delivery models like this one.
Tickeron’s AI Screener has become a regular part of how I screen for ideas across industries. The platform lets users apply technical indicators, fundamentals, volatility measures, trends, AI signals, and custom filters to review thousands of stocks and ETFs. It helps surface names that align with specific strategies without replacing deeper fundamental work.
DocGo occupies a distinct niche as a mobile, technology-supported provider of both medical services and transportation outside conventional facilities. Its two-segment model, clinical reach, and emphasis on home and community care keep it relevant as healthcare delivery evolves toward greater convenience and value-based approaches. Investors tracking this theme may continue to monitor the company’s execution in these areas.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
It is expected that a price bounce should occur soon.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.37% 3-day Advance, the price is estimated to grow further. Considering data from situations where DCGO advanced for three days, in 186 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
DCGO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DCGO as a result. In 77 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The Moving Average Convergence Divergence Histogram (MACD) for DCGO turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 43 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DCGO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for DCGO entered a downward trend on November 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.204) is normal, around the industry mean (204.532). P/E Ratio (-0.126) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.154) among similar stocks. P/S Ratio (0.127) is also within normal values, averaging (2.688).
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. DCGO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DCGO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry HospitalNursingManagement